Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Advances in Platelet Subpopulation Research.

Lesyk G, Jurasz P.

Front Cardiovasc Med. 2019 Sep 13;6:138. doi: 10.3389/fcvm.2019.00138. eCollection 2019. Review.

2.

Potential Antimigraine Effects of Warfarin: An Exploration of Biological Mechanism with Survey of Patients.

Nilsson B, Back V, Wei R, Plane F, Jurasz P, Bungard TJ.

TH Open. 2019 Jun 21;3(2):e180-e189. doi: 10.1055/s-0039-1692989. eCollection 2019 Apr.

3.

STAT3 but Not HIF-1α Is Important in Mediating Hypoxia-Induced Chemoresistance in MDA-MB-231, a Triple Negative Breast Cancer Cell Line.

Soleymani Abyaneh H, Gupta N, Radziwon-Balicka A, Jurasz P, Seubert J, Lai R, Lavasanifar A.

Cancers (Basel). 2017 Oct 14;9(10). pii: E137. doi: 10.3390/cancers9100137.

4.

Differential eNOS-signalling by platelet subpopulations regulates adhesion and aggregation.

Radziwon-Balicka A, Lesyk G, Back V, Fong T, Loredo-Calderon EL, Dong B, El-Sikhry H, El-Sherbeni AA, El-Kadi A, Ogg S, Siraki A, Seubert JM, Santos-Martinez MJ, Radomski MW, Velazquez-Martinez CA, Winship IR, Jurasz P.

Cardiovasc Res. 2017 Dec 1;113(14):1719-1731. doi: 10.1093/cvr/cvx179. Review.

5.

Incorporation of β-actin loading control into zymography.

Govindasamy N, Yan M, Jurasz P.

J Biol Methods. 2016 Nov 1;3(4). pii: e61. doi: 10.14440/jbm.2016.157.

6.

Functional assessment of von Willebrand factor expression by cancer cells of non-endothelial origin.

Mojiri A, Stoletov K, Carrillo MA, Willetts L, Jain S, Godbout R, Jurasz P, Sergi CM, Eisenstat DD, Lewis JD, Jahroudi N.

Oncotarget. 2017 Feb 21;8(8):13015-13029. doi: 10.18632/oncotarget.14273.

7.

CYP1B1 inhibition attenuates doxorubicin-induced cardiotoxicity through a mid-chain HETEs-dependent mechanism.

Maayah ZH, Althurwi HN, Abdelhamid G, Lesyk G, Jurasz P, El-Kadi AO.

Pharmacol Res. 2016 Mar;105:28-43. doi: 10.1016/j.phrs.2015.12.016. Epub 2016 Jan 6.

PMID:
26772815
8.

The role of platelets in the tumor microenvironment: From solid tumors to leukemia.

Yan M, Jurasz P.

Biochim Biophys Acta. 2016 Mar;1863(3):392-400. doi: 10.1016/j.bbamcr.2015.07.008. Epub 2015 Jul 17. Review.

9.

Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: Role of myeloperoxidase and arylamine free radicals.

Khan SR, Baghdasarian A, Nagar PH, Fahlman R, Jurasz P, Michail K, Aljuhani N, Siraki AG.

Chem Biol Interact. 2015 Sep 5;239:129-38. doi: 10.1016/j.cbi.2015.06.020. Epub 2015 Jun 20.

PMID:
26102013
10.

The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival.

Lesyk G, Fong T, Ruvolo PP, Jurasz P.

J Thromb Haemost. 2015 Aug;13(8):1514-20. doi: 10.1111/jth.13010. Epub 2015 Jun 17.

11.

Occlusive lung arterial lesions in endothelial-targeted, fas-induced apoptosis transgenic mice.

Goldthorpe H, Jiang JY, Taha M, Deng Y, Sinclair T, Ge CX, Jurasz P, Turksen K, Mei SH, Stewart DJ.

Am J Respir Cell Mol Biol. 2015 Nov;53(5):712-8. doi: 10.1165/rcmb.2014-0311OC.

PMID:
25879383
12.

PPARδ signaling mediates the cytotoxicity of DHA in H9c2 cells.

Samokhvalov V, Zlobine I, Jamieson KL, Jurasz P, Chen C, Lee KS, Hammock BD, Seubert JM.

Toxicol Lett. 2015 Jan 5;232(1):10-20. doi: 10.1016/j.toxlet.2014.09.029. Epub 2014 Oct 6.

13.

Pharmacological regulation of platelet factors that influence tumor angiogenesis.

Yan M, Lesyk G, Radziwon-Balicka A, Jurasz P.

Semin Oncol. 2014 Jun;41(3):370-7. doi: 10.1053/j.seminoncol.2014.04.007. Epub 2014 Apr 24. Review.

PMID:
25023352
14.

Hypoxia results in upregulation and de novo activation of von Willebrand factor expression in lung endothelial cells.

Mojiri A, Nakhaii-Nejad M, Phan WL, Kulak S, Radziwon-Balicka A, Jurasz P, Michelakis E, Jahroudi N.

Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1329-38. doi: 10.1161/ATVBAHA.113.301359. Epub 2013 Apr 11. Erratum in: Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):e123.

PMID:
23580145
15.

Temporal and pharmacological characterization of angiostatin release and generation by human platelets: implications for endothelial cell migration.

Radziwon-Balicka A, Moncada de la Rosa C, Zielnik B, Doroszko A, Jurasz P.

PLoS One. 2013;8(3):e59281. doi: 10.1371/journal.pone.0059281. Epub 2013 Mar 15.

16.

Pharmacologic protein kinase Cα inhibition uncouples human platelet-stimulated angiogenesis from collagen-induced aggregation.

Moncada de la Rosa C, Radziwon-Balicka A, El-Sikhry H, Seubert J, Ruvolo PP, Radomski MW, Jurasz P.

J Pharmacol Exp Ther. 2013 Apr;345(1):15-24. doi: 10.1124/jpet.112.200881. Epub 2013 Feb 5.

PMID:
23386249
17.

Angiostatin inhibits endothelial MMP-2 and MMP-14 expression: a hypoxia specific mechanism of action.

Radziwon-Balicka A, Ramer C, Moncada de la Rosa C, Zielnik-Drabik B, Jurasz P.

Vascul Pharmacol. 2013 Apr;58(4):280-91. doi: 10.1016/j.vph.2012.11.003. Epub 2012 Dec 7.

PMID:
23220260
18.

Platelet-associated angiogenesis regulating factors: a pharmacological perspective.

Radziwon-Balicka A, Moncada de la Rosa C, Jurasz P.

Can J Physiol Pharmacol. 2012 Jun;90(6):679-88. doi: 10.1139/y2012-036. Epub 2012 Apr 18. Review.

PMID:
22512504
19.

Nitric oxide release is not required to decrease the ulcerogenic profile of nonsteroidal anti-inflammatory drugs.

Jain S, Tran S, El Gendy MA, Kashfi K, Jurasz P, Velázquez-Martínez CA.

J Med Chem. 2012 Jan 26;55(2):688-96. doi: 10.1021/jm200973j. Epub 2012 Jan 10.

PMID:
22148253
20.

VEGF masks BNIP3-mediated apoptosis of hypoxic endothelial cells.

Jurasz P, Yurkova N, Kirshenbaum L, Stewart DJ.

Angiogenesis. 2011 May;14(2):199-207. doi: 10.1007/s10456-011-9204-6. Epub 2011 Feb 13.

PMID:
21318419
21.

Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials.

Jurasz P, Courtman D, Babaie S, Stewart DJ.

Pharmacol Ther. 2010 Apr;126(1):1-8. doi: 10.1016/j.pharmthera.2009.12.006. Epub 2010 Feb 1. Review.

PMID:
20117135
22.

Elevated platelet angiostatin and circulating endothelial microfragments in idiopathic pulmonary arterial hypertension: a preliminary study.

Jurasz P, Ng D, Granton JT, Courtman DW, Stewart DJ.

Thromb Res. 2010 Jan;125(1):53-60. doi: 10.1016/j.thromres.2009.04.005. Epub 2009 May 9.

PMID:
19427678
23.

Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells.

Yacyshyn OK, Lai PF, Forse K, Teichert-Kuliszewska K, Jurasz P, Stewart DJ.

Angiogenesis. 2009;12(1):25-33. doi: 10.1007/s10456-008-9126-0. Epub 2009 Jan 1.

PMID:
19116766
24.

Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.

Nica AF, Tsao CC, Watt JC, Jiffar T, Kurinna S, Jurasz P, Konopleva M, Andreeff M, Radomski MW, Ruvolo PP.

Cell Cycle. 2008 Nov 1;7(21):3362-70. Epub 2008 Nov 2.

25.

Role of metalloproteinases in platelet function.

Santos-Martínez MJ, Medina C, Jurasz P, Radomski MW.

Thromb Res. 2008;121(4):535-42. Epub 2007 Aug 2. Review.

PMID:
17681591
26.

Generation of platelet angiostatin mediated by urokinase plasminogen activator: effects on angiogenesis.

Jurasz P, Santos-Martinez MJ, Radomska A, Radomski MW.

J Thromb Haemost. 2006 May;4(5):1095-106.

27.

Protein kinase C delta mediates platelet-induced breast cancer cell invasion.

Alonso-Escolano D, Medina C, Cieslik K, Radomski A, Jurasz P, Santos-Martínez MJ, Jiffar T, Ruvolo P, Radomski MW.

J Pharmacol Exp Ther. 2006 Jul;318(1):373-80. Epub 2006 Apr 14.

PMID:
16617167
28.

Platelet aggregation-induced by caco-2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate.

Medina C, Jurasz P, Santos-Martinez MJ, Jeong SS, Mitsky T, Chen R, Radomski MW.

J Pharmacol Exp Ther. 2006 May;317(2):739-45. Epub 2006 Jan 19.

PMID:
16424148
29.

Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients.

Chrapko W, Jurasz P, Radomski MW, Archer SL, Newman SC, Baker G, Lara N, Le Mellédo JM.

Neuropsychopharmacology. 2006 Jun;31(6):1286-93.

30.

Nanoparticle-induced platelet aggregation and vascular thrombosis.

Radomski A, Jurasz P, Alonso-Escolano D, Drews M, Morandi M, Malinski T, Radomski MW.

Br J Pharmacol. 2005 Nov;146(6):882-93.

31.

Platelet-leukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases.

Chung AW, Radomski A, Alonso-Escolano D, Jurasz P, Stewart MW, Malinski T, Radomski MW.

Br J Pharmacol. 2004 Dec;143(7):845-55. Epub 2004 Nov 8.

32.

Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation.

Jurasz P, Alonso-Escolano D, Radomski MW.

Br J Pharmacol. 2004 Dec;143(7):819-26. Epub 2004 Oct 18. Review.

33.

Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder.

Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Mellédo JM.

Biol Psychiatry. 2004 Jul 15;56(2):129-34.

PMID:
15231445
34.

Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study.

Jurasz P, North S, Venner P, Radomski MW.

Thromb Res. 2003;112(1-2):59-64. No abstract available.

PMID:
15013275
35.

Generation and role of angiostatin in human platelets.

Jurasz P, Alonso D, Castro-Blanco S, Murad F, Radomski MW.

Blood. 2003 Nov 1;102(9):3217-23. Epub 2003 Jul 10.

PMID:
12855585
36.

Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels.

Ulrich ML, Rotzinger S, Asghar SJ, Jurasz P, Tanay VA, Dunn SM, Radomski M, Greenshaw A, Silverstone PH.

J Psychiatry Neurosci. 2003 Mar;28(2):115-25.

37.

Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets.

Radomski A, Jurasz P, Sanders EJ, Overall CM, Bigg HF, Edwards DR, Radomski MW.

Br J Pharmacol. 2002 Dec;137(8):1330-8.

38.

Nonremodeling properties of matrix metalloproteinases: the platelet connection.

Jurasz P, Chung AW, Radomski A, Radomski MW.

Circ Res. 2002 May 31;90(10):1041-3. No abstract available.

PMID:
12039792
39.

Mechanisms of action of proteinase-activated receptor agonists on human platelets.

Chung AW, Jurasz P, Hollenberg MD, Radomski MW.

Br J Pharmacol. 2002 Mar;135(5):1123-32.

40.

Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin.

Jurasz P, Stewart MW, Radomski A, Khadour F, Duszyk M, Radomski MW.

Br J Pharmacol. 2001 Nov;134(5):1104-12.

41.

Pharmacological characteristics of solid-phase von Willebrand factor in human platelets.

Radomski A, Stewart MW, Jurasz P, Radomski MW.

Br J Pharmacol. 2001 Nov;134(5):1013-20.

42.

Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide.

Jurasz P, Sawicki G, Duszyk M, Sawicka J, Miranda C, Mayers I, Radomski MW.

Cancer Res. 2001 Jan 1;61(1):376-82.

43.

Determination of cell surface charge by photometric titration.

Thethi K, Jurasz P, MacDonald AJ, Befus AD, Man SF, Duszyk M.

J Biochem Biophys Methods. 1997 Mar 27;34(2):137-45.

PMID:
9178089
44.

[Current aspects of locomotor pathology: benign tumors manifested in sports practice].

Feron F, Jurasz P, Crielaard JM.

Rev Med Liege. 1993 Mar;48(3):159-66. French. No abstract available.

PMID:
8469861

Supplemental Content

Loading ...
Support Center